APO Research
Talk to an analyst

APO RESEARCH · REPORT

Daclatasvir

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Daclatasvir Industry Growth and Trends Forecast to 2032

23 December 2025101 pages

Choose your research edition.

Industry ResearchDaclatasvir Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Daclatasvir Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Daclatasvir Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Daclatasvir Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Daclatasvir Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Daclatasvir market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Daclatasvir is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Daclatasvir is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Daclatasvir is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Daclatasvir include Abbott, Mylan, Bristol-Myers Squibb, Zydus Cadila, Torrent Pharmaceuticals, Natco Pharma, Hetero Drugs, Emcure Pharmaceuticals and Dr Reddy's Laboratories, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Daclatasvir market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Daclatasvir market size, estimates, and forecasts are presented in terms of sales volume (k pcs) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Daclatasvir market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Daclatasvir.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Daclatasvir market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Daclatasvir Market by Company

Abbott

Mylan

Bristol-Myers Squibb

Zydus Cadila

Torrent Pharmaceuticals

Natco Pharma

Hetero Drugs

Emcure Pharmaceuticals

Dr Reddy's Laboratories

Cipla

Biocon

Daclatasvir Segment by Type

30mg Tables

60mg Tables

Daclatasvir Segment by Application

Hepatitis C Virus (HCV) Genotype 4

Hepatitis C Virus (HCV) Genotype 3

Hepatitis C Virus (HCV) Genotype 1

Daclatasvir Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Daclatasvir market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Daclatasvir and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Daclatasvir.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Daclatasvir manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Daclatasvir in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of 30mg Tables Table 2. Major Company of 60mg Tables Table 3. Global Daclatasvir Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Daclatasvir Sales by Type (2021-2026) & (k pcs) Table 5. Global Daclatasvir Sales Market Share in Volume by Type (2021-2026) Table 6. Global Daclatasvir Sales by Type (2021-2026) & (US$ Million) Table 7. Global Daclatasvir Sales Market Share in Value by Type (2021-2026) Table 8. Global Daclatasvir Price by Type (2021-2026) & (US$/pcs) Table 9. Global Daclatasvir Sales by Type (2027-2032) & (k pcs) Table 10. Global Daclatasvir Sales Market Share in Volume by Type (2027-2032) Table 11. Global Daclatasvir Sales by Type (2027-2032) & (US$ Million) Table 12. Global Daclatasvir Sales Market Share in Value by Type (2027-2032) Table 13. Global Daclatasvir Price by Type (2027-2032) & (US$/pcs) Table 14. North America Daclatasvir Sales by Type (2021-2026) & (k pcs) Table 15. North America Daclatasvir Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Daclatasvir Sales by Type (2021-2026) & (k pcs) Table 17. Europe Daclatasvir Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Daclatasvir Sales by Type (2021-2026) & (k pcs) Table 19. Asia-Pacific Daclatasvir Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Daclatasvir Sales by Type (2021-2026) & (k pcs) Table 21. Latin America Daclatasvir Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Daclatasvir Sales by Type (2021-2026) & (k pcs) Table 23. Middle East and Africa Daclatasvir Sales by Type (2021-2026) & (US$ Million) Table 24. Daclatasvir Industry Trends Table 25. Daclatasvir Industry Drivers Table 26. Daclatasvir Industry Opportunities and Challenges Table 27. Daclatasvir Industry Restraints Table 28. Global Daclatasvir Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Daclatasvir Revenue Market Share by Company (2021-2026) Table 30. Global Daclatasvir Sales by Company (2021-2026) & (k pcs) Table 31. Global Daclatasvir Sales Share by Company (2021-2026) Table 32. Global Daclatasvir Market Price by Company (2021-2026) & (US$/pcs) Table 33. Global Daclatasvir Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Daclatasvir Major Company Production Sites and Headquarters Table 35. Global Daclatasvir Company, Product Type & Application Table 36. Global Daclatasvir Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Daclatasvir by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Daclatasvir Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Daclatasvir Sales by Region (2021-2026) & (k pcs) Table 41. Global Daclatasvir Sales Market Share in Volume by Region (2021-2026) Table 42. Global Daclatasvir Sales by Region (2021-2026) & (US$ Million) Table 43. Global Daclatasvir Sales Market Share in Value by Region (2021-2026) Table 44. Global Daclatasvir Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 45. Global Daclatasvir Sales by Region (2027-2032) & (k pcs) Table 46. Global Daclatasvir Sales Market Share in Volume by Region (2027-2032) Table 47. Global Daclatasvir Sales by Region (2027-2032) & (US$ Million) Table 48. Global Daclatasvir Sales Market Share in Value by Region (2027-2032) Table 49. Global Daclatasvir Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2027-2032) Table 50. Global Daclatasvir Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Daclatasvir Sales by Application (2021-2026) & (k pcs) Table 52. Global Daclatasvir Sales Market Share in Volume by Application (2021-2026) Table 53. Global Daclatasvir Sales by Application (2021-2026) & (US$ Million) Table 54. Global Daclatasvir Sales Market Share in Value by Application (2021-2026) Table 55. Global Daclatasvir Price by Application (2021-2026) & (US$/pcs) Table 56. Global Daclatasvir Sales by Application (2027-2032) & (k pcs) Table 57. Global Daclatasvir Sales Market Share in Volume by Application (2027-2032) Table 58. Global Daclatasvir Sales by Application (2027-2032) & (US$ Million) Table 59. Global Daclatasvir Sales Market Share in Value by Application (2027-2032) Table 60. Global Daclatasvir Price by Application (2027-2032) & (US$/pcs) Table 61. North America Daclatasvir Sales by Application (2021-2026) & (k pcs) Table 62. North America Daclatasvir Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Daclatasvir Sales by Application (2021-2026) & (k pcs) Table 64. Europe Daclatasvir Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Daclatasvir Sales by Application (2021-2026) & (k pcs) Table 66. Asia-Pacific Daclatasvir Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Daclatasvir Sales by Application (2021-2026) & (k pcs) Table 68. Latin America Daclatasvir Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Daclatasvir Sales by Application (2021-2026) & (k pcs) Table 70. Middle East and Africa Daclatasvir Sales by Application (2021-2026) & (US$ Million) Table 71. Abbott Company Information Table 72. Abbott Business Overview Table 73. Abbott Daclatasvir Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 74. Abbott Daclatasvir Product Portfolio Table 75. Abbott Recent Development Table 76. Mylan Company Information Table 77. Mylan Business Overview Table 78. Mylan Daclatasvir Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 79. Mylan Daclatasvir Product Portfolio Table 80. Mylan Recent Development Table 81. Bristol-Myers Squibb Company Information Table 82. Bristol-Myers Squibb Business Overview Table 83. Bristol-Myers Squibb Daclatasvir Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 84. Bristol-Myers Squibb Daclatasvir Product Portfolio Table 85. Bristol-Myers Squibb Recent Development Table 86. Zydus Cadila Company Information Table 87. Zydus Cadila Business Overview Table 88. Zydus Cadila Daclatasvir Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 89. Zydus Cadila Daclatasvir Product Portfolio Table 90. Zydus Cadila Recent Development Table 91. Torrent Pharmaceuticals Company Information Table 92. Torrent Pharmaceuticals Business Overview Table 93. Torrent Pharmaceuticals Daclatasvir Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 94. Torrent Pharmaceuticals Daclatasvir Product Portfolio Table 95. Torrent Pharmaceuticals Recent Development Table 96. Natco Pharma Company Information Table 97. Natco Pharma Business Overview Table 98. Natco Pharma Daclatasvir Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 99. Natco Pharma Daclatasvir Product Portfolio Table 100. Natco Pharma Recent Development Table 101. Hetero Drugs Company Information Table 102. Hetero Drugs Business Overview Table 103. Hetero Drugs Daclatasvir Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 104. Hetero Drugs Daclatasvir Product Portfolio Table 105. Hetero Drugs Recent Development Table 106. Emcure Pharmaceuticals Company Information Table 107. Emcure Pharmaceuticals Business Overview Table 108. Emcure Pharmaceuticals Daclatasvir Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 109. Emcure Pharmaceuticals Daclatasvir Product Portfolio Table 110. Emcure Pharmaceuticals Recent Development Table 111. Dr Reddy's Laboratories Company Information Table 112. Dr Reddy's Laboratories Business Overview Table 113. Dr Reddy's Laboratories Daclatasvir Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 114. Dr Reddy's Laboratories Daclatasvir Product Portfolio Table 115. Dr Reddy's Laboratories Recent Development Table 116. Cipla Company Information Table 117. Cipla Business Overview Table 118. Cipla Daclatasvir Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 119. Cipla Daclatasvir Product Portfolio Table 120. Cipla Recent Development Table 121. Biocon Company Information Table 122. Biocon Business Overview Table 123. Biocon Daclatasvir Sales (k pcs), Revenue (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 124. Biocon Daclatasvir Product Portfolio Table 125. Biocon Recent Development Table 126. North America Daclatasvir Market Size Growth Rate (CAGR) by Country (k pcs): 2021 VS 2025 VS 2032 Table 127. North America Daclatasvir Sales by Country (2021-2026) & (k pcs) Table 128. North America Daclatasvir Sales Market Share by Country (2021-2026) Table 129. North America Daclatasvir Sales Forecast by Country (2027-2032) & (k pcs) Table 130. North America Daclatasvir Sales Market Share Forecast by Country (2027-2032) Table 131. North America Daclatasvir Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 132. North America Daclatasvir Market Size by Country (2021-2026) & (US$ Million) Table 133. North America Daclatasvir Market Share by Country (2021-2026) Table 134. North America Daclatasvir Market Size Forecast by Country (2027-2032) & (US$ Million) Table 135. North America Daclatasvir Market Share Forecast by Country (2027-2032) Table 136. Europe Daclatasvir Market Size Growth Rate (CAGR) by Country (k pcs): 2021 VS 2025 VS 2032 Table 137. Europe Daclatasvir Sales by Country (2021-2026) & (k pcs) Table 138. Europe Daclatasvir Sales Market Share by Country (2021-2026) Table 139. Europe Daclatasvir Sales Forecast by Country (2027-2032) & (k pcs) Table 140. Europe Daclatasvir Sales Market Share Forecast by Country (2027-2032) Table 141. Europe Daclatasvir Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 142. Europe Daclatasvir Market Size by Country (2021-2026) & (US$ Million) Table 143. Europe Daclatasvir Market Share by Country (2021-2026) Table 144. Europe Daclatasvir Market Size Forecast by Country (2027-2032) & (US$ Million) Table 145. Europe Daclatasvir Market Share Forecast by Country (2027-2032) Table 146. Asia-Pacific Daclatasvir Market Size Growth Rate (CAGR) by Country (k pcs): 2021 VS 2025 VS 2032 Table 147. Asia-Pacific Daclatasvir Sales by Country (2021-2026) & (k pcs) Table 148. Asia-Pacific Daclatasvir Sales Market Share by Country (2021-2026) Table 149. Asia-Pacific Daclatasvir Sales Forecast by Country (2027-2032) & (k pcs) Table 150. Asia-Pacific Daclatasvir Sales Market Share Forecast by Country (2027-2032) Table 151. Asia-Pacific Daclatasvir Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 152. Asia-Pacific Daclatasvir Market Size by Country (2021-2026) & (US$ Million) Table 153. Asia-Pacific Daclatasvir Market Share by Country (2021-2026) Table 154. Asia-Pacific Daclatasvir Market Size Forecast by Country (2027-2032) & (US$ Million) Table 155. Asia-Pacific Daclatasvir Market Share Forecast by Country (2027-2032) Table 156. Latin America Daclatasvir Market Size Growth Rate (CAGR) by Country (k pcs): 2021 VS 2025 VS 2032 Table 157. Latin America Daclatasvir Sales by Country (2021-2026) & (k pcs) Table 158. Latin America Daclatasvir Sales Market Share by Country (2021-2026) Table 159. Latin America Daclatasvir Sales Forecast by Country (2027-2032) & (k pcs) Table 160. Latin America Daclatasvir Sales Market Share Forecast by Country (2027-2032) Table 161. Latin America Daclatasvir Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 162. Latin America Daclatasvir Market Size by Country (2021-2026) & (US$ Million) Table 163. Latin America Daclatasvir Market Share by Country (2021-2026) Table 164. Latin America Daclatasvir Market Size Forecast by Country (2027-2032) & (US$ Million) Table 165. Latin America Daclatasvir Market Share Forecast by Country (2027-2032) Table 166. Middle East and Africa Daclatasvir Market Size Growth Rate (CAGR) by Country (k pcs): 2021 VS 2025 VS 2032 Table 167. Middle East and Africa Daclatasvir Sales by Country (2021-2026) & (k pcs) Table 168. Middle East and Africa Daclatasvir Sales Market Share by Country (2021-2026) Table 169. Middle East and Africa Daclatasvir Sales Forecast by Country (2027-2032) & (k pcs) Table 170. Middle East and Africa Daclatasvir Sales Market Share Forecast by Country (2027-2032) Table 171. Middle East and Africa Daclatasvir Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 172. Middle East and Africa Daclatasvir Market Size by Country (2021-2026) & (US$ Million) Table 173. Middle East and Africa Daclatasvir Market Share by Country (2021-2026) Table 174. Middle East and Africa Daclatasvir Market Size Forecast by Country (2027-2032) & (US$ Million) Table 175. Middle East and Africa Daclatasvir Market Share Forecast by Country (2027-2032) Table 176. Key Raw Materials Table 177. Raw Materials Key Suppliers Table 178. Daclatasvir Distributors List Table 179. Daclatasvir Customers List Table 180. Research Programs/Design for This Report Table 181. Authors List of This Report Table 182. Secondary Sources Table 183. Primary Sources List of Figures Figure 1. Daclatasvir Image Figure 2. Global Daclatasvir Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Daclatasvir Market Size (2021-2032) & (US$ Million) Figure 4. Global Daclatasvir Sales (2021-2032) & (k pcs) Figure 5. 30mg Tables Image Figure 6. Global 30mg Tables Sales YoY Growth (2021-2032) & (k pcs) Figure 7. 60mg Tables Image Figure 8. Global 60mg Tables Sales YoY Growth (2021-2032) & (k pcs) Figure 9. Global Daclatasvir Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Daclatasvir Market Share by Type 2025 VS 2032 Figure 11. North America Daclatasvir Sales Market Share in Volume by Type in 2025 Figure 12. North America Daclatasvir Sales Market Share in Value by Type in 2025 Figure 13. Europe Daclatasvir Sales Market Share in Volume by Type in 2025 Figure 14. Europe Daclatasvir Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Daclatasvir Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Daclatasvir Sales Market Share in Value by Type in 2025 Figure 17. Latin America Daclatasvir Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Daclatasvir Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Daclatasvir Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Daclatasvir Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Daclatasvir Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Hepatitis C Virus (HCV) Genotype 4 Image Figure 24. Global Hepatitis C Virus (HCV) Genotype 4 Sales YoY Growth (2021-2032) & (k pcs) Figure 25. Hepatitis C Virus (HCV) Genotype 3 Image Figure 26. Global Hepatitis C Virus (HCV) Genotype 3 Sales YoY Growth (2021-2032) & (k pcs) Figure 27. Hepatitis C Virus (HCV) Genotype 1 Image Figure 28. Global Hepatitis C Virus (HCV) Genotype 1 Sales YoY Growth (2021-2032) & (k pcs) Figure 29. Global Daclatasvir Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Daclatasvir Market Share by Application 2025 VS 2032 Figure 31. North America Daclatasvir Sales Market Share in Volume by Application in 2025 Figure 32. North America Daclatasvir Sales Market Share in Value by Application in 2025 Figure 33. Europe Daclatasvir Sales Market Share in Volume by Application in 2025 Figure 34. Europe Daclatasvir Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific Daclatasvir Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific Daclatasvir Sales Market Share in Value by Application in 2025 Figure 37. Latin America Daclatasvir Sales Market Share in Volume by Application in 2025 Figure 38. Latin America Daclatasvir Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa Daclatasvir Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa Daclatasvir Sales Market Share in Value by Application in 2025 Figure 41. North America Daclatasvir Sales by Country: 2021 VS 2025 VS 2032 (k pcs) Figure 42. North America Daclatasvir Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America Daclatasvir Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America Daclatasvir Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Daclatasvir Sales by Country: 2021 VS 2025 VS 2032 (k pcs) Figure 46. Europe Daclatasvir Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Daclatasvir Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Daclatasvir Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Daclatasvir Sales by Country: 2021 VS 2025 VS 2032 (k pcs) Figure 50. Asia-Pacific Daclatasvir Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Daclatasvir Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific Daclatasvir Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Daclatasvir Sales by Country: 2021 VS 2025 VS 2032 (k pcs) Figure 54. Latin America Daclatasvir Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Daclatasvir Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Daclatasvir Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Daclatasvir Sales by Country: 2021 VS 2025 VS 2032 (k pcs) Figure 58. Middle East and Africa Daclatasvir Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Daclatasvir Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa Daclatasvir Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Daclatasvir Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. Daclatasvir Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • 30mg Tables
  • 60mg Tables
Applications
  • Hepatitis C Virus (HCV) Genotype 4
  • Hepatitis C Virus (HCV) Genotype 3
  • Hepatitis C Virus (HCV) Genotype 1
Companies covered
  • Abbott
  • Mylan
  • Bristol-Myers Squibb
  • Zydus Cadila
  • Torrent Pharmaceuticals
  • Natco Pharma
  • Hetero Drugs
  • Emcure Pharmaceuticals
  • Dr Reddy's Laboratories
  • Cipla
  • Biocon

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Daclatasvir Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Daclatasvir Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Daclatasvir Market by Type
  6. 1.3.1 30mg Tables
  7. 1.3.2 60mg Tables
  8. 1.4 Global Daclatasvir Market Size by Type
  9. 1.4.1 Global Daclatasvir Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Daclatasvir Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Daclatasvir Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Daclatasvir Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Daclatasvir Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Daclatasvir Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Daclatasvir Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Daclatasvir Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Daclatasvir Industry Trends
  2. 2.2 Daclatasvir Industry Drivers
  3. 2.3 Daclatasvir Industry Opportunities and Challenges
  4. 2.4 Daclatasvir Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Daclatasvir Revenue (2021-2026)
  2. 3.2 Global Top Players by Daclatasvir Sales (2021-2026)
  3. 3.3 Global Top Players by Daclatasvir Price (2021-2026)
  4. 3.4 Global Daclatasvir Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Daclatasvir Major Company Production Sites & Headquarters
  6. 3.6 Global Daclatasvir Company, Product Type & Application
  7. 3.7 Global Daclatasvir Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Daclatasvir Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Daclatasvir Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Daclatasvir Tier 1, Tier 2, and Tier 3
4 Daclatasvir Regional Status and Outlook
  1. 4.1 Global Daclatasvir Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Daclatasvir Historic Market Size by Region
  3. 4.2.1 Global Daclatasvir Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Daclatasvir Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Daclatasvir Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Daclatasvir Forecasted Market Size by Region
  7. 4.3.1 Global Daclatasvir Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Daclatasvir Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Daclatasvir Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Daclatasvir by Application
  1. 5.1 Daclatasvir Market by Application
  2. 5.1.1 Hepatitis C Virus (HCV) Genotype 4
  3. 5.1.2 Hepatitis C Virus (HCV) Genotype 3
  4. 5.1.3 Hepatitis C Virus (HCV) Genotype 1
  5. 5.2 Global Daclatasvir Market Size by Application
  6. 5.2.1 Global Daclatasvir Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Daclatasvir Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Daclatasvir Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Daclatasvir Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Daclatasvir Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Daclatasvir Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Daclatasvir Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Daclatasvir Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Abbott
  2. 6.1.1 Abbott Company Information
  3. 6.1.2 Abbott Business Overview
  4. 6.1.3 Abbott Daclatasvir Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Abbott Daclatasvir Product Portfolio
  6. 6.1.5 Abbott Recent Developments
  7. 6.2 Mylan
  8. 6.2.1 Mylan Company Information
  9. 6.2.2 Mylan Business Overview
  10. 6.2.3 Mylan Daclatasvir Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Mylan Daclatasvir Product Portfolio
  12. 6.2.5 Mylan Recent Developments
  13. 6.3 Bristol-Myers Squibb
  14. 6.3.1 Bristol-Myers Squibb Company Information
  15. 6.3.2 Bristol-Myers Squibb Business Overview
  16. 6.3.3 Bristol-Myers Squibb Daclatasvir Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Bristol-Myers Squibb Daclatasvir Product Portfolio
  18. 6.3.5 Bristol-Myers Squibb Recent Developments
  19. 6.4 Zydus Cadila
  20. 6.4.1 Zydus Cadila Company Information
  21. 6.4.2 Zydus Cadila Business Overview
  22. 6.4.3 Zydus Cadila Daclatasvir Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Zydus Cadila Daclatasvir Product Portfolio
  24. 6.4.5 Zydus Cadila Recent Developments
  25. 6.5 Torrent Pharmaceuticals
  26. 6.5.1 Torrent Pharmaceuticals Company Information
  27. 6.5.2 Torrent Pharmaceuticals Business Overview
  28. 6.5.3 Torrent Pharmaceuticals Daclatasvir Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Torrent Pharmaceuticals Daclatasvir Product Portfolio
  30. 6.5.5 Torrent Pharmaceuticals Recent Developments
  31. 6.6 Natco Pharma
  32. 6.6.1 Natco Pharma Company Information
  33. 6.6.2 Natco Pharma Business Overview
  34. 6.6.3 Natco Pharma Daclatasvir Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Natco Pharma Daclatasvir Product Portfolio
  36. 6.6.5 Natco Pharma Recent Developments
  37. 6.7 Hetero Drugs
  38. 6.7.1 Hetero Drugs Company Information
  39. 6.7.2 Hetero Drugs Business Overview
  40. 6.7.3 Hetero Drugs Daclatasvir Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Hetero Drugs Daclatasvir Product Portfolio
  42. 6.7.5 Hetero Drugs Recent Developments
  43. 6.8 Emcure Pharmaceuticals
  44. 6.8.1 Emcure Pharmaceuticals Company Information
  45. 6.8.2 Emcure Pharmaceuticals Business Overview
  46. 6.8.3 Emcure Pharmaceuticals Daclatasvir Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Emcure Pharmaceuticals Daclatasvir Product Portfolio
  48. 6.8.5 Emcure Pharmaceuticals Recent Developments
  49. 6.9 Dr Reddy's Laboratories
  50. 6.9.1 Dr Reddy's Laboratories Company Information
  51. 6.9.2 Dr Reddy's Laboratories Business Overview
  52. 6.9.3 Dr Reddy's Laboratories Daclatasvir Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Dr Reddy's Laboratories Daclatasvir Product Portfolio
  54. 6.9.5 Dr Reddy's Laboratories Recent Developments
  55. 6.10 Cipla
  56. 6.10.1 Cipla Company Information
  57. 6.10.2 Cipla Business Overview
  58. 6.10.3 Cipla Daclatasvir Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Cipla Daclatasvir Product Portfolio
  60. 6.10.5 Cipla Recent Developments
  61. 6.11 Biocon
  62. 6.11.1 Biocon Company Information
  63. 6.11.2 Biocon Business Overview
  64. 6.11.3 Biocon Daclatasvir Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Biocon Daclatasvir Product Portfolio
  66. 6.11.5 Biocon Recent Developments
7 North America by Country
  1. 7.1 North America Daclatasvir Sales by Country
  2. 7.1.1 North America Daclatasvir Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Daclatasvir Sales by Country (2021-2026)
  4. 7.1.3 North America Daclatasvir Sales Forecast by Country (2027-2032)
  5. 7.2 North America Daclatasvir Market Size by Country
  6. 7.2.1 North America Daclatasvir Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Daclatasvir Market Size by Country (2021-2026)
  8. 7.2.3 North America Daclatasvir Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Daclatasvir Sales by Country
  2. 8.1.1 Europe Daclatasvir Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Daclatasvir Sales by Country (2021-2026)
  4. 8.1.3 Europe Daclatasvir Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Daclatasvir Market Size by Country
  6. 8.2.1 Europe Daclatasvir Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Daclatasvir Market Size by Country (2021-2026)
  8. 8.2.3 Europe Daclatasvir Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Daclatasvir Sales by Country
  2. 9.1.1 Asia-Pacific Daclatasvir Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Daclatasvir Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Daclatasvir Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Daclatasvir Market Size by Country
  6. 9.2.1 Asia-Pacific Daclatasvir Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Daclatasvir Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Daclatasvir Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Daclatasvir Sales by Country
  2. 10.1.1 South America Daclatasvir Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Daclatasvir Sales by Country (2021-2026)
  4. 10.1.3 South America Daclatasvir Sales Forecast by Country (2027-2032)
  5. 10.2 South America Daclatasvir Market Size by Country
  6. 10.2.1 South America Daclatasvir Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Daclatasvir Market Size by Country (2021-2026)
  8. 10.2.3 South America Daclatasvir Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Daclatasvir Sales by Country
  2. 11.1.1 Middle East and Africa Daclatasvir Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Daclatasvir Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Daclatasvir Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Daclatasvir Market Size by Country
  6. 11.2.1 Middle East and Africa Daclatasvir Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Daclatasvir Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Daclatasvir Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Daclatasvir Value Chain Analysis
  2. 12.1.1 Daclatasvir Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Daclatasvir Production Mode & Process
  7. 12.2 Daclatasvir Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Daclatasvir Distributors
  10. 12.2.3 Daclatasvir Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst